RecruitingPhase 3

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)

Lead sponsor

Pfizer

Assets

MET097 / PF-08653944 / Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

660

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•Body weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07845500

Org study IDC6491015

Timeline

Milestones

Study first posted2026-09-29actual

Study start2026-09-30actual

Last update posted2026-11-05actual

Primary completion2028-02-16estimated

Study completion2028-02-16estimated

Assets

Investigational agents

MET097 / PF-08653944 Semaglutide Tirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Aged ≥18 years.

•Currently taking semaglutide or tirzepatide for obesity management.

Exclusion criteria

•Diagnosis of any form of diabetes.

•History of acute or chronic pancreatitis.

•Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

2 endpoints

Primary/protocol endpoint

Percent change from baseline in body weight

Time frame:Baseline, Week 32

percent change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in body weight

Time frame:Baseline, Week 32

change from baseline, improvement

Safety / tolerability / PK

5 endpoints

Secondary/protocol endpoint

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Time frame:Baseline, Week 32

event count, event

Secondary/protocol endpoint

Number of Participants with Serious adverse events (SAEs)

Time frame:Baseline, Week 32

event count, event

Secondary/protocol endpoint

Number of Participants with adverse events leading to discontinuation

Time frame:Baseline, Week 32

event count, event

Secondary/protocol endpoint

Number of Participants with Adverse Events of Special Interest (AESIs)

Time frame:Baseline, Week 32

event count, event

Secondary/protocol endpoint

Number of Participants with Clinical Laboratory Abnormalities

Time frame:Baseline, Week 32

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.